A summary of the most recent meeting of the Patient Engagement Collaborative (PEC) is now available. The PEC, which is convened jointly by the FDA and CTTI to discuss how the FDA can bolster patient engagement in its activities, met in September in Rockville, Md.
The primary objective of the PEC’s meeting was to discuss an FDA Ambassador program, which emerged from the group’s March 2019 meeting as a potential avenue to help the patient community engage with the FDA. The PEC discussed potential audiences for the program, as well as the most effective ways to communicate with these audiences. The collaborative also discussed changes the FDA plans to make to its website to make it easier for patients to navigate.
The PEC, which was established in December 2017, is composed of 16 members representing diverse patient communities across the U.S. CTTI and FDA are extending the terms of the initial members by one year, and look forward to engaging new perspectives through an open call for new nominations as current member complete terms in 2021 and 2022. This effort is facilitated by provisions in the 21st Century Cures Act of 2016 and the Food and Drug Administration Reauthorization Act of 2017.
To learn more about other efforts by CTTI and the FDA to further patient engagement, please attend CTTI's webinar, "Patient Engagement in Action: Insights from Patients & the FDA" on Nov. 17 at noon ET.